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Abstract
Background: Hyperlipidemia is a condition that is characterized as an increase in total cholesterol and triglyceride levels in the
blood. Lactoferrin is a protein that can serve as an antioxidant. This study aims to determine whether lactoferrin can reduce total
cholesterol and triglyceride levels.
Methods: This study used 24 Sprague–Dawley rat strains, which were divided into six groups: normal group; negative control;
positive control; and dose groups 1, 2, and 3. The normal group was given standard feed, whereas the other group was given high
cholesterol and fat. The positive control group and dose groups 1, 2, and 3 were given 1.5 mg/kg BW of simvastatin and 100, 200,
and 400 mg/kg of BW lactoferrin, respectively. After 6 weeks, total cholesterol and triglyceride levels were measured.
Results: This study showed that lactoferrin doses of 100, 200, and 400 mg/kg BW could significantly reduce total cholesterol and
triglyceride levels (p < 0.05). Lactoferrin could also significantly reduce activated Kupffer cell and steatosis area in the liver (p < 0.05).
Conclusions: Lactoferrin can reduce total cholesterol and triglyceride levels. Thus, further research is needed to address the
existing bias and confirm that lactoferrin can reduce cholesterol and triglyceride levels.
Keywords: cholesterol, hyperlipidemia, lactoferrin, sprague–Dawley, triglyceride

INTRODUCTION

hyperlipidemia is due to low physical activity, smoking,
diabetes mellitus, nephritic syndrome, hypothyroidism,
and drug use. Complications from hyperlipidemia
condition include atherosclerosis, coronary artery
disease, myocardial infarct, and ischemic stroke.6 At
present, statin is a common medication for treating
hyperlipidemia; however, this medication still has side
effects such as myalgia.7,8 Many types of research are
conducted on the basis of this condition, such as
lactoferrin research in reducing lipid profile levels.9

Hyperlipidemia is a common cause of atherosclerotic
plaque formation in coronary arteries.1 An increase in total
cholesterol and triglyceride levels shows hyperlipidemia.2,3
Hyperlipidemia, also known as dyslipidemia, is a common
condition, which is associated with cardiovascular
diseases, with elevated plasma low-density lipoprotein
(LDL) cholesterol being the 8th leading risk factor of death
in 2019.4 Approximately 4.4 million deaths and 98.62
million disabilities were related to high-plasma LDLcholesterol. Based on data from Indonesia Basic Health
Research 2018, 35.9% of people in Indonesia aged 15
years and above have abnormal lipid profiles, of which
5.9% have a high level of LDL, 22.9% have a low level of
high-density lipoprotein, and 11.9% have a high level of
triglyceride.5

Lactoferrin is an iron-binding glycoprotein in the body.
Mammals such as cows, horses, dogs, and humans can
produce lactoferrin.10 Lactoferrin plays an important role
in the physiological function of the human body, such as
antimicrobial, antiviral, immune system enhancement,
and antioxidants.10 Antioxidants from lactoferrin can
reduce total cholesterol and triglyceride levels in the
blood as well as the steatosis area in the liver. The high
affinity for the binding of lactoferrin to iron in the body
can prevent the production of free radicals during the
Fenton reaction, thereby inhibiting the oxidation of
lipoproteins in the body.11 A study conducted by Nozari et
al. showed that bovine lactoferrin reduces total
cholesterol and triglyceride levels in male rats fed with
high-cholesterol diet.12 However, no in vivo studies in
Indonesia had been conducted to assess the potential

Hyperlipidemia could be divided into primary
hyperlipidemia and secondary hyperlipidemia. Primary
hyperlipidemia is due to heredity, whereas secondary
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application of lactoferrin in reducing total cholesterol and
triglyceride levels in hyperlipidemia-induced male rats.
Thus, this paper aims to examine the potential application
of lactoferrin as antihyperlipidemia in hyperlipidemiainduced male Sprague–Dawley male rats.12
METHODS
All experiments performed in this study were approved by
the ethical review committee of School Medicine and
Health Sciences—the Atma Jaya Catholic University of
Indonesia on January 20, 2021 (protocol number
01/01/KEP-FKIKUAJ/2021), and all procedures were in
accordance with international standards for animal
experimentation. This experimental study was conducted
from April 2021 until June 2021 at Pharmacology
Laboratory and Animal House School of Medicine Atma
Jaya Catholic University of Indonesia, Jakarta. Bovine
lactoferrin was purchased from Xi’an Ruisaen
Biotechnology Co., Ltd., China, as water-soluble pinkishwhite crystals with purity of 99% (RSN201119).
Male Sprague–Dawley rat strains (N = 30) aged 5 weeks,
with 150–200 g body weight, were obtained from the
Indonesian Food Drug Administration Laboratory Service
(certificate no. 02/LHP/SKKH/IV/2021). Subjects were
calculated on the basis of the degree of freedom or
resource equation method formula. The minimum sample
size of at least four Sprague–Dawley rats was obtained for
each group based on the formula. This study used a sample
of four rats per study group. The total number of samples
in each study group was added by 10% to five rats to
overcome the dropout. Subjects were randomly divided
into six experimental groups. The first group was the
normal group fed a normal diet. The second group was
composed of hypercholesterolemic rats fed a highcholesterol diet (HCD) containing 15% sucrose, 5% cow’s fat,
80% quail egg yolk, and 0.01% propylthiouracil (PTU). The
third group was given orally HCD and 1.5 gr/150 g BW
simvastatin therapy. The fourth, fifth, and sixth groups
were given HCD and lactoferrin doses of 100, 200, and 400
mg/kg BW, respectively. All groups were fed HCD for 3
weeks except for the normal group, and then the third
group was given simvastatin. The fourth, fifth, and sixth
groups were given lactoferrin for 3 weeks. After induction
of hyperlipidemia, all groups except for the normal group
were still given HCD for another 3 weeks.
After 6 weeks of research, all rats were necropsied. Two
milliliters of rat blood were drawn through the rat’s heart
and placed into the Eppendorf tube. We kept the sample
for around 45 min until the blood clotted, and then the
sample was centrifuged for around 30 min with 1500 g of
power on 400C. Next, we collected 10 μL of serum and
placed into the plastic cuvette. Afterward, 1000 μL of
reagent kit was mixed with 10 μL of the sample in the plastic
cuvette, and then the mixture was incubated for 10 min at
20 °C–25 °C or for 5 min at 37 °C. Absorbance was read
Makara J Health Res.

within 60 min against reagent blank at a wavelength range
of 500–546 nm. Total cholesterol levels were measured by
cholesterol FS (10′) reagent (manufactured by DiaSys
Diagnostic Systems GmbH, Germany). However, triglyceride
levels were measured by triglyceride FS (10′) reagent
(manufactured by DiaSys Diagnostic Systems GmbH,
Germany).
The total cholesterol level was measured as follows:
𝐴𝑏𝑠 𝑆𝑎𝑚𝑝𝑙𝑒
Cholesterol (mg/dL) =
× Cholesterol Standard
(mg/dL)

𝐴𝑏𝑠 𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑

The triglycerides level was measured as follows:
𝐴𝑏𝑠 𝑆𝑎𝑚𝑝𝑙𝑒
Triglyceride (mg/dL) =
× Triglyceride Standard
(mg/dL)

𝐴𝑏𝑠 𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑

All livers were fixed using formaldehyde and collected to
the anatomic pathology laboratory to slice the tissue
samples and stain with hematoxylin and eosin. Steatosis in
the liver was scored on the basis of the method of Kleiner
et al. This method determined steatosis based on the
following percentage: grade 0, <5% steatosis; grade 1, 5–
33% steatosis; grade 2, 33–66% steatosis; grade 3, >66%
steatosis.13 The activated Kupffer cell was scored in
accordance with the method of the Arsad et al. This method
was used to measure activated Kupffer cells in sinusoid,
which were graded as follows: grade 0, 0% activated Kupffer
cell; grade 1, <30% activated Kupffer cell; grade 2, 30–50%
activated Kupffer cell; grade 3, >50% activated Kupffer cell.14
Three microscopic fields of view were selected for each
slide, and histopathological changes were analyzed under a
light microscope with 400× magnification.
SPSS for MacOs (SPSS, Chicago, IL, USA) version 28 was used
for statistical analyses. Data were shown as means ± SD.
One-way ANOVA was used to test established variance
analysis. Tukey post hoc test was used to assess the
significance of differences among groups (if the
homogeneity of variables and normality distribution was
assumed). P < 0.05 was considered statistically significant.
Data for activated Kupffer cell and steatosis were analyzed
by Kruskal–Wallis test followed by Mann–Whitney test to
compare group differences.
RESULTS
All data were analyzed by one-way ANOVA and then Tukey
post hoc test. The result of one-way ANOVA showed a
significant difference among all groups (p < 0.05). The
effect of bovine lactoferrin treatment on total cholesterol
and triglyceride alteration in experimental animals is
shown in Table 1. The total cholesterol and triglyceride
levels were significantly higher in the HCD group than in
the normal group (p < 0.05). Total cholesterol and
triglyceride levels were significantly lower in bovine
lactoferrin treatment in all dose groups than in the HCD
group (p < 0.05). In addition, no significant changes were
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observed between the normal group and all bovine
lactoferrin dose groups. No significant difference was also
found between all bovine lactoferrin dose groups and the
positive control group. Similarly, no significant difference
was observed among dose groups 1, 2, and 3. Dose group
2 had the lowest total cholesterol level and triglyceride
level compared with the other dose groups; however,
dose group 3 had the highest total cholesterol level and
triglyceride level compared with the other dose groups.
All lobes (right lobe, left lobe, quadrate lobe, and caudate
lobe) from the liver were examined in this study.
Histopathological analysis showed that rats from the HCD
group had fatty livers. However, lipid accumulation
reduces in groups administered with lactoferrin. This
condition was supported by a higher steatosis score in the
HCD group compared with the normal group (Table 2; p <
0.05). The lactoferrin treatment group had significantly
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lower histopathological steatosis scores than the control
group (Table 2; p < 0.05) Lipid accumulation can increase
oxidative stress, characterized by the activation of Kupffer
cells in the liver. The activated Kupffer cell score was
significantly higher in the HCD group than in the normal
and lactoferrin treatment groups (Table 2; p < 0.001). No
significant difference in activated Kupffer cell score was
found among the normal group, positive control group,
and groups administered with lactoferrin (Figure 1). Many
activated Kupffer cells were found in negative control rats
(Figure 1A) compared with the normal group (Figure 1B).
Activated Kupffer cells were also shown to be minimal in
the positive control group (Figure 1C), dose 1 group
(Figure 1D), dose 2 group (Figure 1E), and dose 3 group
(Figure 1F). As shown in the picture, lactoferrin dose 2
group has least activated Kupffer cells compared with the
other lactoferrin dose groups.

TABLE 1. Effects of bovine lactoferrin on total cholesterol and triglyceride in male rats
Parameter

Normal

HCD

Total Cholesterol (mg/dL) 84,440  36,641a 157,514  40,010 b
Triglyceride (mg/dL)

39,741  16,380a 70,818  14,385b

HCD + 1,5 mg/150
g BW Simvastatin

HCD + 100
mg/kg BW bLf

HCD + 200
mg/kg BW bLf

HCD + 400
mg/kg BW bLf

76,435  2,470a

73,043  28,765a 71,604  23,572a 78,781  23,093a

36,044  8,819a

35,669  10,983a 31,747  7,140a 39,927  17,381a

HCD: high-cholesterol diet; bLF: bovine lactoferrin.
Different letters in the same row indicate a significant difference (p < 0.05).

TABLE 2. Effects of bovine lactoferrin on activated Kupffer cells and steatosis score in the liver
Parameter

Normal

HCD

HCD + 1,5 mg/150 g
BW Simvastatin

HCD + 100
HCD + 200
HCD + 400
mg/kg BW bLf mg/kg BW bLf mg/kg BW bLf

Activated Kupffer Cell Score

0.83 ± 0.389a

2.42 ± 0.515b

1.08 ± 0.515a

0.75 ± 0.452a

0.42 ± 0.515a

1.17 ± 0.577a

Steatosis Score

0.00 ± 0.000a

2.58 ± 0.515b

1.58 ± 0.669c

1.33 ± 0.888c

1.00 ± 0.739c

2.00 ± 0.739c

HCD: high-cholesterol diet; bLF: bovine lactoferrin.
Different letters in the same row indicate a significant difference (p < 0.05).

A

B

C

D

E

F

FIGURE 1. Histopathologic examination of rat liver. (A) negative control shows several activated Kupffer cells, (B) normal
control (C), positive control, (D) dose 1 (E) dose 2, and (F) dose 3 shows minimal activated Kupffer cells.
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DISCUSSION
This study analyzes antihyperlipidemia from lactoferrin by
measuring blood total cholesterol and triglyceride levels
and performing microscopic liver analyses. Histopathological
analyses measured the amount of activated Kupffer cells
and steatosis score in rat liver. The results show that
bovine lactoferrin treatment could decrease total
cholesterol and triglyceride levels in male Sprague–
Dawley rats, commonly at risk of cardiovascular diseases.
High-sucrose consumption can increase lipid profile levels
such as total cholesterol, triglycerides, VLDL, NASH,
NAFLD, and insulin resistance. Insulin resistance is a
condition where insulin’s ability to suppress glucose and
VLDL production is impaired; thus, TG will be released to
the bloodstream through VLDL lipoproteins, leading to
dyslipidemia.15 Another food that can induce
hyperlipidemia is cow’s fat because 100 g of cow’s fat
contains 126 mg of cholesterol.16 PTU can also induce
hyperlipidemia by inhibiting the thyroid hormone. Thyroid
hormones will activate the LDL receptor-related protein 1
(LRP1). LRP1 is a receptor that binds lipid-conjugated
apolipoprotein E (ApoE) and internalizes triglyceride-rich
lipoproteins containing ApoE, such as chylomicron
remnants and LDL remnant, thereby contributing to the
clearance of chylomicron. The consumption of PTU will
reduce the expression of LRP1 receptors, thereby
increasing the LDL levels in the bloodstream.17
Lactoferrin promotes lipid absorption through the
stimulation of bile acid synthesis. The lactoferrin pathway
inhibits the production of TNF-.18 TNF- is a
proinflammatory cytokine that inhibits the expression of
HNF4A.19 HNF4A is a gene that activates the CYP7A1
enzyme.20 The HNF4A gene makes instructions for making
a protein, namely, hepatocyte nuclear factor-4 alpha.21
This protein contributes to the development of the liver,
kidney, and intestine; however, CYP7A1 is a catalyzed
enzyme for converting cholesterol to bile acids.22 By
phosphorylating AMP-activated protein kinase (AMPK),
lactoferrin serves as an agonist of AMPK, which is a
protein that regulates energy homeostasis and
coordinates metabolic pathways, thereby balancing
nutrient supply with energy demand. Two enzymes (FAS
and ACC) and genes (SERBP1) are controlled by AMPK.23
SERBP1 is a mediator of hepatic lipogenesis, which is overinduced in obese animals; however, FAS and ACC are the
key enzymes for lipid synthesis, and ATGL is the main
enzyme
for
triglyceride
degradation.24–26
The
supplementation of LF can decrease the expression of
SERBP1, inhibit the protein expression of FAS and ACC,
and elevate the protein expression of ATGL. Therefore,
lactoferrin decreases lipid synthesis and increases the
degradation of lipid in the liver.23,27 These research results
are consistent with a study conducted by Faridvand et al.,
Makara J Health Res.

who stated that bovine lactoferrin can reduce lipid
profiles such as total cholesterol and triglyceride levels in
rats induced with a HCD. This lipid profile–lowering effect
follows the role of lactoferrin as an antioxidant in
inhibiting lipid synthesis in the body.28 Nakamura et al.
reported that lactoferrin could significantly reduce
hepatic cholesterol levels in rats by increasing cholesterol
excretion through interaction with bile acids.9
Our data showed that the decrease in total cholesterol
and triglyceride levels was not consistent with the
increase in lactoferrin dose. 200 mg/kg BW of lactoferrin
had the lowest total cholesterol and triglyceride levels;
thus, this dose was considered as optimal for decreasing
total cholesterol and triglyceride levels. Nozari et al. also
showed that 200 mg/kg BW of lactoferrin could reduce
total cholesterol and triglyceride levels.12 Hence, further
research is recommended to ensure that 200 mg/kg BW is
the optimal dose for lactoferrin in lowering total
cholesterol and triglyceride levels. In addition, 400 mg/kg
BW of lactoferrin had higher total cholesterol and
triglyceride levels than the other doses. A high dose of
lactoferrin can reduce cell proliferation by inhibiting the
activation of extracellular signal-regulated kinase, releasing
IL-8 cytokines, increasing NF-Kβ, and activating hypoxiainducible factor-1α (HIF-1α).29 Therefore, excessively high
lactoferrin dose can increase the inflammatory effect,
thereby promoting cholesterol synthesis.
A similar effect was found in microscopic analysis of the
liver, where the steatosis area score was significantly
lower in the group administered with lactoferrin
compared with the HCD group. That is, lactoferrin could
be a potential drug to prevent fatty liver. Lactoferrin also
has an antioxidant effect, thereby preventing lipid
accumulation in the liver. This condition indicates that
activated Kupffer cells were significantly higher in the HCD
group than in the lactoferrin treatment group. Activated
Kupffer cell is a physiological response of the liver to injury
or infection. High-fat diets can increase gut permeability
and trigger the accumulation of lipopolysaccharides. The
binding of LPS to their receptors on Kupffer cell surface
promotes the production and secretion of cytokines that
recruit T and B lymphocytes and other leukocytes;
therefore, activated Kupffer cells can indicate
dyslipidemia.30 Recent studies have also shown that
lactoferrin could treat fatty liver and serve as an
antioxidant.31
Statin is a common class of drugs that reduce cholesterol
levels in the blood. Their mechanism of action is primarily
via the inhibition of HMG-CoA (hydroxymethylglutarylcoenzyme-A) reductase, which is the enzyme responsible
for the cholesterol biosynthetic pathway. Statin could
lower LDL-c and reduce cardiovascular morbidity and
mortality, in primary and secondary prevention; however,
statin has some serious side effects. Statin toxicity or
intolerance is commonly presented as statin-associated
December 2022 | Vol. 26 | No. 3
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muscle symptoms). Another side effects of statin therapy,
which can be more serious, include new-onset type 2
diabetes mellitus, neurological and neurocognitive effects,
hepatotoxicity, renal toxicity, and other conditions.
Mechanistically, statin toxicity can arise because of HMGCoA reductase inhibition effects, direct cellular and
subcellular effects, or a combination of both. Other
possible causes include genetic factors, drug–drug
interactions, vitamin D status, and other metabolic or
immune effects.32
This research still had some limitations from various
aspects during the research process. Differences in the
amount of normal feeding to rats were found among the
groups, and not all food given using a probe could be
swallowed completely by rats. The researchers could not
assess the average total cholesterol and triglyceride levels
before and after the intervention with lactoferrin.
Therefore, further research is necessary to measure total
cholesterol and triglyceride levels before and after
intervention with lactoferrin.
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CONCLUSIONS
Bovine lactoferrin could be used in treating patients with
hyperlipidemia. In addition, 100, 200, and 400 mg/kg BW
of lactoferrin could reduce total cholesterol and
triglyceride levels to normal levels.
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